ACTRN12618001710213已完成1 期
Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DB-020 in Healthy Volunteers
Decibel Therapeutics Australia Pty Ltd0 个研究点目标入组 42 人开始时间: 2018年10月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 50 Years（—）
- 性别
- All
入选标准
- •1. Ability to communicate with medical team and staff, willingness to participate in the study, willingness to give written informed consent, and willingness to comply with the study restrictions.
- •2. Healthy men and women aged 18 to 50 years, inclusive, at screening.
- •3. Weight: greater than or equal to 50.0 kg.
- •4. Body mass index (BMI): 18.0 to 32.0 kg/m^2, inclusive. BMI = Body weight (kg)/Height^2 (m^2)]
- •5. The absence of evidence of any clinically significant, in the opinion of the Investigator, active or chronic medical or psychiatric disease or pathology after a detailed medical and surgical history, a complete physical examination including vital signs measurements, 12-lead ECG, and clinical laboratory tests (hematology, serum chemistry, serology, and urinalysis).
- •6. All values for hematology and for clinical chemistry tests of serum and urine are within the normal range or showing no clinically relevant deviations, as judged by the Investigator, during screening and on the day of admission to the clinical facility.
- •7. Ability and willingness to abstain from alcohol, caffeine, and xanthine-containing beverages or food (eg, coffee, tea, cola, chocolate, diet pills, energy drinks) from 48 hours (2 days) before check-in until the final follow-up visit.
- •8. Male subjects, their female partner(s), and female subjects of childbearing potential must agree to use 2 forms of contraception, 1 of which must be a barrier method, during the study and for 90 days after study drug administration. Acceptable barrier forms of contraception are condom and diaphragm. Acceptable forms of contraception for this study for female partner(s) of childbearing potential and premenopausal female subjects are nonhormonal and hormonal intrauterine device (IUD), hormonal birth control pills, hormonal birth control patches, hormonal birth control injections [eg, Depo-Provera(R)], hormonal birth control implants, and NuvaRing(R). Male and female subjects who consider themselves abstinent, and who agree to remain abstinent during the study and for 90 days after study drug administration, will be eligible to participate in the study. Women of nonchildbearing potential are eligible for the study and are defined as 12 months with no menses before screening and a follicle-stimulating hormone (FSH) level greater than 40 IU/L during screening (ie, postmenopausal female subjects), or surgically sterile female subjects, eg, those having undergone total abdominal hysterectomy, bilateral oophorectomy, or bilateral tubal ligation at least 6 months before screening for study participation. Surgically sterile female subjects may participate if they agree to use condoms during the study and for 90 days after study drug administration. Male subjects who have undergone a vasectomy at least 6 months before Screening and who have a documented negative sperm count (eg, medical records or single semen specimen) after the procedure are not required to use contraception.
- •9. Male subjects must agree to refrain from sperm donation within 90 days after study drug administration.
- •10. Hearing threshold of 25 dB or better in both ears as assessed with audiometry before randomization.
- •11. Normal otoscopic examination of both ears (absence of significant scarring of ear canal or tympanic membrane, absence of narrow ear canal preventing injection, etc.).
- •12. Must be willing to agree to avoid strenuous exercise, sunbathing, and contact sports for the period starting 7 days prior to c
排除标准
- •Subjects meeting any of the following exclusion criteria are not to be randomized to study treatment:
- •1. Female or male subjects with female partners who are pregnant, lactating, or planning to attempt to become pregnant during this study or within 90 days after dosing of study drug.
- •2. Sustained supine systolic blood pressure greater than 139 or less than 90 mm Hg and supine diastolic blood pressure greater than 89 or less than 50 mm Hg at screening or any day of admission to the clinical facility.
- •3. Resting heart rate less than 40 beats per minute or greater than 100 beats per minute during screening or on the day of admission to the clinical facility.
- •4. ECG during screening showing corrected QT interval using Fridericia correction formula (QTcF) greater than or equal to 450 msec. In addition, subjects with any other risk factors for QT/QTcF prolongation or any abnormality in the ECG that, in the opinion of the Investigator, increases the risk of participating in the study will be excluded.
- •5. Positive results for drugs of abuse, alcohol, or cotinine in the urine at screening or any day of admission to the clinical facility.
- •6. Positive screening test for hepatitis B surface antigen, hepatitis C antibody, and/or human immunodeficiency virus (HIV) antibodies.
- •7. Use of any medication (prescription or over-the-counter (OTC), including health supplements and herbal remedies, with the exception of acetaminophen as defined below) within 2 weeks (4 weeks for enzyme inducers including St. John’s Wort [Hypericum perforatum]) or 5 half-lives (whichever is longer) before the first dose of study drug.
- •8. Routine or chronic use of more than 2 g of acetaminophen daily.
- •9. Use of any investigational drug or device within 30 days of the first dose of study drug (6 months for biologic therapies) or 5 half-lives of the investigational drug, if known, whichever time period is longer.
- •10. Exposure to excessively loud noise (eg, concerts, loud noise at the workplace) within 24 to 48 hours before Day 1.
- •11. History of donation of more than 450 mL of blood within 60 days before dosing in the clinical research center or planned donation before 30 days have elapsed since intake of study drug. This will be verified by the subject’s hemoglobin and hematocrit values. Subjects with clinically significant abnormalities in hemoglobin/hematocrit will be excluded from the study.
- •12. Plasma, white blood cell, or platelet donation within 7 days of study participation and throughout the study.
- •13. Lack of venous access or inability to tolerate venipuncture as determined by the Investigator or designee.
- •14. History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) and/or allergy to the excipients of the study drug.
- •15. Current smoker, currently using e-cigarettes, or discontinuation of smoking or use of e-cigarettes less than 45 days before the first dose of study drug.
- •16. History (within 3 months of Screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 g of alcohol).
- •17. Any major surgery within 4 weeks of study drug administration.
- •18. History or presence of malignancy within the past 5 years other than past history of localized or surgical removal of focal basal cell skin cancer; cervical cancer in situ treated successfully in the past by local treatment (including but not limited to cryotherapy or laser therapy) or by hysterectomy.
- •19. Previous participation in the study.
研究者
相似试验
已完成
1 期
A study to investigate how ENTR-601-44 behaves in the body, the safety and how well tolerated different increasing amounts of the drug ENTR-601-44 are when given to healthy male volunteersHealthy volunteersISRCTN36174912Entrada Therapeutics, Inc.32
招募中
1 期
A Phase 1 Study of MAXONA Pharmaceuticals MAX-001 healthy subjects for the evaluation of safety, tolerability, and drug concentrations in progressively increasing single and multiple daily dose levelsVarious pain indicationsAnaesthesiology - Pain managementACTRN12622001351707George Clinical Pty Ltd60
尚未招募
1 期
A study to evaluate the safety, tolerability, and pharmacokinetics of a single dose of the drug F-652 in healthy male volunteers.Alcoholic HepatitisInflammatory and Immune System - Other inflammatory or immune system disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12612000713897Generon Corporation Ltd40
尚未招募
1 期
Ascending single doses of a novel Interlukin (IL-1 ) agonist administered to healthy subjects.Auto-immune inflammatory diseaseInflammatory and Immune System - Autoimmune diseasesACTRN12609000891224Hutchison MediPharma32
尚未招募
1 期
Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RPH-203 Following a Single Dose in Healthy Male VolunteersBone MetastasisCancer - BoneMusculoskeletal - OsteoporosisOsteoporosisACTRN12613000651785ucleus Network Limited48